SEC Filings
State Street Holds 5.1% Of CareDx Without Seeking To Influence Control
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
CareDx (CDNA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding totaled 2,623,064 shares, alongside CareDx's higher 2026 revenue outlook.
Earnings
CEO John Hanna says the cell-therapy relapse test launches in the first quarter of 2027, built natively into Epic ordering from the first day.
Earnings
The fourth-quarter model assumes $1,550 per transplant test, and management sees NavDx pricing climbing toward $1,000 or more.
Earnings
The transplant-testing company also raised its 2026 revenue forecast to $520 million to $530 million on third-quarter sales of $139 million.
Earnings
A $9.8 million valuation allowance release lifted third-quarter net income, while operations earned $8.1 million.